Ard M D, Cole G M, Wei J, Mehrle A P, Fratkin J D
Department of Anatomy, University of Mississippi Medical Center, Jackson 39216, USA.
J Neurosci Res. 1996 Jan 15;43(2):190-202. doi: 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B.
Deposits of amyloid beta-protein (A beta) form the cores of the pathological plaques which characterize Alzheimer's disease. The mechanism of formation of the deposits is unknown; one possibility is failure of a clearance mechanism that would normally remove the protein from brain parenchyma. This study has investigated the capacity of the central nervous system (CNS) phagocytes, microglia cells, to clear exogenous A beta 1-42 from their environment. Cultured microglia from adult rat CNS have a high capacity to remove A beta from serum-free medium, shown by immunoblotting experiments. A beta from incubation medium was attached to the cell surface and could be identified by immunocytochemistry at the light or electron microscopic (EM) level; by EM, A beta also appeared in phagosome-like intracellular vesicles. Light microscopic immunocytochemistry combined with computer-assisted image analysis showed that cells accumulated A beta within 24 hr. from culture medium containing from 1 to 20 micrograms/ml A beta. Microglial accumulation of A beta was substantially reduced in the presence of fetal bovine serum. Addition of the protease inhibitor leupeptin to incubation medium with serum resulted in accumulation of A beta in a membrane-bound intracellular compartment, but not at the cell surface. The increase in intracellular accumulation in the presence of the protease inhibitor indicates a microglial capacity for intracellular degradation of A beta in the absence of inhibition. The change from predominantly cell-surface accumulation in serum-free medium to predominantly intracellular accumulation with serum may be explained by the presence in serum of carrier proteins that complex with A beta and target it to cell surface receptors capable of stimulating endocytosis. Microglia were also cultured on unfixed cryostat sections of human brain tissue containing Alzheimer's plaques. Very little A beta from the tissue was accumulated by the cells, although cultured microglia were found in direct contact with anti-A beta immunopositive plaques. Possibly A beta in tissue sections was complexed with other proteins which either inhibited its uptake by microglia or enhanced its proteolysis, preventing cellular accumulation of immunostainable A beta. The results indicate that cultured microglia effectively remove A beta from tissue culture medium and from the surface of the dish and concentrate monomer and aggregates of A beta either on the cell surface or intracellularly. This process may be modified by proteins present in Alzheimer's brain sections.
β-淀粉样蛋白(Aβ)沉积物构成了阿尔茨海默病特征性病理斑块的核心。沉积物的形成机制尚不清楚;一种可能性是正常情况下将该蛋白从脑实质中清除的清除机制出现故障。本研究调查了中枢神经系统(CNS)吞噬细胞——小胶质细胞从其周围环境中清除外源性Aβ1-42的能力。免疫印迹实验表明,来自成年大鼠中枢神经系统的培养小胶质细胞具有从无血清培养基中清除Aβ的高能力。孵育培养基中的Aβ附着在细胞表面,可通过光镜或电镜(EM)水平的免疫细胞化学鉴定;通过电镜观察,Aβ也出现在吞噬体样的细胞内囊泡中。光镜免疫细胞化学结合计算机辅助图像分析表明,细胞在24小时内从含有1至20微克/毫升Aβ的培养基中积累了Aβ。在胎牛血清存在的情况下,小胶质细胞对Aβ的积累显著减少。向含血清的孵育培养基中添加蛋白酶抑制剂亮抑酶肽会导致Aβ在膜结合的细胞内区室中积累,但不会在细胞表面积累。在存在蛋白酶抑制剂的情况下细胞内积累的增加表明小胶质细胞在没有抑制作用时具有细胞内降解Aβ的能力。从无血清培养基中主要在细胞表面积累到有血清时主要在细胞内积累的变化,可能是由于血清中存在与Aβ结合并将其靶向能够刺激内吞作用的细胞表面受体的载体蛋白。小胶质细胞也在含有阿尔茨海默病斑块的人脑组织未固定低温切片上培养。尽管发现培养的小胶质细胞与抗Aβ免疫阳性斑块直接接触,但细胞从组织中积累的Aβ很少。可能组织切片中的Aβ与其他蛋白质结合,这些蛋白质要么抑制其被小胶质细胞摄取,要么增强其蛋白水解作用,从而阻止免疫可染色的Aβ在细胞内积累。结果表明,培养的小胶质细胞能有效地从组织培养基和培养皿表面清除Aβ,并将Aβ的单体和聚集体集中在细胞表面或细胞内。阿尔茨海默病脑切片中存在的蛋白质可能会改变这一过程。